相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cancer statistics, 2022
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2022)
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
Kirsten L. Bryant et al.
NATURE MEDICINE (2019)
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
Ryan J. Sullivan et al.
CANCER DISCOVERY (2018)
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
Andrew M. Waters et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
ERK Inhibition: A New Front in the War against MAPK Pathway-Driven Cancers?
Inna Smalley et al.
CANCER DISCOVERY (2018)
Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models
Hongmei Jiang et al.
MOLECULAR CANCER THERAPEUTICS (2018)
KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism
Angelina V. Vaseva et al.
CANCER CELL (2018)
Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
Ursula A. Germann et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression
Tikvah K. Hayes et al.
CANCER CELL (2016)
Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer
Clifford J. Whatcott et al.
CLINICAL CANCER RESEARCH (2015)
Whole genomes redefine the mutational landscape of pancreatic cancer
Nicola Waddell et al.
NATURE (2015)
Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study
Stefano Cascinu et al.
DIGESTIVE AND LIVER DISEASE (2014)
A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
Jeffrey R. Infante et al.
EUROPEAN JOURNAL OF CANCER (2014)
Mutationally Activated PIK3CAH1047R Cooperates with BRAFV600E to Promote Lung Cancer Progression
Christy L. Trejo et al.
CANCER RESEARCH (2013)
Tumor adaptation and resistance to RAF inhibitors
Piro Lito et al.
NATURE MEDICINE (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Andrew V. Biankin et al.
NATURE (2012)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?
Dominico Vigil et al.
NATURE REVIEWS CANCER (2010)
A Gene Expression Signature Associated with K-Ras Addiction Reveals Regulators of EMT and Tumor Cell Survival
Anurag Singh et al.
CANCER CELL (2009)
分享论文
